Rapid Micro Biosystems develops and markets the Growth Direct automated microbial quality control detection platform, which helps pharmaceutical and biopharmaceutical manufacturers accelerate and simplify contamination testing in the production of biologics, cell and gene therapies, vaccines, and sterile injectables. The company sells its platform—comprising hardware, proprietary consumables, optional software, and associated services—to pharmaceutical manufacturers worldwide, generating revenue from both one-time system and software sales and recurring consumables and service contracts. The company earns recurring revenue from consumables used in the platform and from post-sale service contracts, while also capturing non-recurring revenue from initial system purchases, validation services, and software licensing.